Clinical trials: Iron-Deficiency
Iron Deficiency Anemia
A Study Comparing Two Ferric Carboxymaltose Formulations in Patients With Iron Deficiency Anemia
This study will evaluate bioequivalence of two formulations of Ferric Carboxymaltose as measured by serum total iron, in adult patients with iron deficiency anemia.
- Trial name
- NCT03399084
- Testing
- Ferric carboxymaltose
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Sandoz
Iron Deficiency Anemia
Effectiveness and Acceptability of LISEFEX® (Liposomal Iron With Vitamin C and Fiber) in People With Iron Deficiency Anemia.
Observational, descriptive, prospective, longitudinal, multicenter, non-interventionist and multicentric study in Mexican subjects diagnosed with mild to moderate iron deficiency anemia (ADH).
- Trial name
- NCT07483645
- Where
- Mexico
- Volunteers
- 74 people
- Sponsor
- Carnot Laboratories
Iron Deficiency Anaemia, Iron Deficiency Anemia
Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
The trial was designed to evaluate the incidence of unintended hypophosphatemia (low level of phosphate in the blood) in subjects with iron deficiency anaemia (IDA).
- Trial name
- NCT03237065
- Testing
- Iron isomaltoside/ferric derisomaltose, Ferric carboxymaltose
- Where
- 15 sites in United States
- Volunteers
- 122 people
- Sponsor
- Pharmacosmos A/S
Iron Deficiency Anemia of Pregnancy
Intravenous Iron Isomaltoside Versus Oral Iron Supplementation for Treatment of Iron Deficiency in Pregnancy.
Intravenous iron isomaltoside versus oral iron supplementation for treatment of iron deficiency in pregnancy
- Trial name
- NCT03188445
- Testing
- Iron Isomaltoside 1000, ferrous fumarate with ascorbic acid
- Where
- Denmark
- Volunteers
- 201 people
- Sponsor
- Pharmacosmos A/S
Iron Deficiency Anemia
Efficacy and Safety Study of Iron Sucrose and Oral Iron Acetyl-transferrin Hydroglycerin
multi-center, prospective, randomized, open-labeled, active-drug-controlled, two-parallel-group-comparison(venoferrun group vs Bolgre group)study
- Trial name
- NCT00802139
- Testing
- venoferrum(iron sucrose), Bolgre (Iron acetyl-transferase)
- Where
- 3 sites in South Korea
- Volunteers
- 58 people
- Sponsor
- JW Pharmaceutical
Heart Failure, Iron-deficiency
Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study
The primary objective of this study is to determine the efficacy and safety of iron therapy using intravenous (IV) ferric carboxymaltose (FCM), relative to placebo in the treatment of participants in heart failure with a reduced…
- Trial name
- HEART-FID (NCT03037931)
- Testing
- Ferric Carboxymaltose
- Where
- 345 sites in United States, Australia and 11 more
- Volunteers
- 3,065 people
- Sponsor
- American Regent, Inc.
Hereditary Hemochromatosis
A Study to Evaluate BBI-001 in Hereditary Haemochromatosis (HH) Patients and Iron Deficient Volunteers
This is a first in human, double-blind, randomized, placebo-controlled, two-arm crossover study evaluating the safety, tolerability and PD of ascending dose levels of BBI-001 after: a single administration in iron deficient male…
- Trial name
- NCT05238207
- Testing
- BBI-001, Original Fibre Metamucil
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bond Biosciences
Restless Legs Syndrome (RLS)
Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in RLS Patients With Iron-deficiency Anemia
Treatment Phase I and II Primary Objective: To evaluate the efficacy and safety of FCM (750 mg dose x 2) for treatment of Restless Legs Syndrome (RLS) in patients with iron-deficiency anemia (IDA).
- Trial name
- NCT02826681
- Testing
- Injectafer® (Ferric Carboxymaltose - FCM)
- Where
- 8 sites in United States
- Volunteers
- 70 people
- Sponsor
- American Regent, Inc.
Iron Deficiency, Chronic Heart Failure
A Study to Compare the Use of Ferric Carboxymaltose With Placebo in Patients With Chronic Heart Failure and Iron Deficiency
The purpose of this study is to determine, relative to placebo, the effect of iron repletion therapy using intravenous (IV) ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency.
- Trial name
- CONFIRM-HF (NCT01453608)
- Testing
- Ferinject (ferric carboxymaltose)
- Where
- 2 sites in Poland, Russia
- Volunteers
- 304 people
- Sponsor
- Vifor Pharma
Iron Deficiency, Anaemia in Children, Iron-Deficiency
Evaluate the PK, Safety, Tolerability of Ferric Maltol at 3 Dosage Levels in Paediatric Subjects With Iron Deficiency
The study has been designed to establish the pharmacokinetics (PK) and iron uptake of Ferric Maltol in children and adolescents aged 10-17 years using two (2) lower dose strengths in comparison to the EU-approved 30mg BID dose in…
- Trial name
- NCT03181451
- Testing
- Ferric Maltol
- Where
- 7 sites in United Kingdom
- Volunteers
- 37 people
- Sponsor
- Shield Therapeutics
Diagnostic
Study of the Prevalence of Iron Deficiency in Patients With Scheduled Major Surgery (CARENFER PBM)
Many patients who are candidates for scheduled major surgery have a pre-operative iron deficiency which is poorly diagnosed. The management of per-operative iron deficiency is a part of the concept of the "Patient Blood…
- Trial name
- CARENFER-PBM (NCT04800042)
- Testing
- Diagnostic test
- Volunteers
- 1,700 people
- Sponsor
- VIFORFRANCE
Mild and Moderate Iron-deficiency Anaemia
Study to Test the Hypothesis of Non-inferior Efficacy and Safety of Ferrum Lek® (Iron (III) Hydroxide Polymaltosate), 100 mg Chewable Tablets (Lek d.d., Slovenia), as Compared With MALTOFER® (Vifor S.A., Switzerland), in Subjects With Mild and Moderate Iron Deficiency Anemia.
The purpose of this study was to evaluate non-inferiority for efficacy and safety of Ferrum Lek® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Lek d.d., Slovenia), compared to MALTOFER® (Vifor S.A., Switzerland)…
- Trial name
- NCT03993288
- Testing
- Ferrum Lek® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Lek d.d., Slovenia), MALTOFER® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Vifor S.A., Switzerland)
- Where
- 18 sites in Russia
- Volunteers
- 267 people
- Sponsor
- Sandoz
Iron Deficiency Anemia
Ferrous Sulphate Supplement (V0355) in Women With Iron Deficiency Anaemia
The purpose of this study is to investigate the pharmacokinetics of serum iron after a single oral administration of 160 mg (2 tablets of 80 mg) V0355 in women with iron deficiency anaemia.
- Trial name
- NCT02518568
- Testing
- V0355
- Where
- 2 sites in Bulgaria, Romania
- Volunteers
- 29 people
- Sponsor
- Pierre Fabre Medicament
Anaemia in Chronic Kidney Disease
A Non-interventional Study of Diafer in Subjects With CKD on Haemodialysis for Treatment of Iron Deficiency
The purpose of the study is to monitor initiated Diafer® therapy administered according to hospital practice and the product labeling in routine clinical practice in haemodialysis patients with Chronic Kidney Disease.
- Trial name
- DINO (NCT02301026)
- Testing
- 5% Iron Isomaltoside 1000
- Where
- 2 sites in Sweden, United Kingdom
- Volunteers
- 209 people
- Sponsor
- Pharmacosmos A/S
Anemia, Iron-Deficiency
A Two-part Single- and Repeat-dose Study of CSJ137 in Anemic Chronic Hemodialysis Patients
The study will assess the safety, tolerability and efficacy of CSJ137 in chronic hemodialysis patients. It is hypothesized that treatment with CSJ137 may improve the level of hemoglobin in patients on chronic hemodialysis with…
- Trial name
- NCT02570854
- Testing
- CSJ137
- Where
- 13 sites in United States, Czechia and 2 more
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Iron Deficiency Anemia Treatment, Chronic Kidney Disease(CKD)
Compare Efficacy/Safety of Repeat Doses of Ferumoxytol With Iron Sucrose in CKD Subjects With IDA and on Hemodialysis
The objectives of this study are to compare the efficacy and safety of repeat doses of intravenous (IV) ferumoxytol with IV iron sucrose for the treatment of IDA in subjects with hemodialysis-dependent CKD.
- Trial name
- NCT01227616
- Testing
- Ferumoxytol, Iron Sucrose
- Where
- 43 sites in United States, Canada and 1 more
- Volunteers
- 296 people
- Sponsor
- AMAG Pharmaceuticals, Inc.
Anemia, Iron-deficiency
Evaluate the Safety and Efficacy of Ferric Maltol Oral Suspension vs. Ferrous Sulfate Oral Liquid in Children and Adolescents Aged 2 to 17 Years With Iron-deficiency Anaemia, With a Single Arm Study in Infants Aged 1 Month to Less Than 2 Years
The objective of the study is to compare the safety and gastrointestinal tolerability of ferric maltol oral suspension and ferrous sulfate oral liquid in children and adolescents aged 2 years to 17 years, and assess the safety…
- Trial name
- FORTIS (NCT05126901)
- Testing
- Ferric Maltol, Ferrous sulfate
- Where
- 23 sites in United States, Puerto Rico and 1 more
- Volunteers
- 65 people
- Sponsor
- Shield Therapeutics
Iron Deficiency Anemia
A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency Anemia
To evaluate the efficacy and safety of intravenous (IV) ferumoxytol compared with placebo for the treatment of iron deficiency anemia (IDA).
- Trial name
- NCT01114139
- Testing
- Ferumoxytol
- Where
- 182 sites in United States, Canada and 4 more
- Volunteers
- 812 people
- Sponsor
- AMAG Pharmaceuticals, Inc.
Anemia
Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency Anemia
The objective of this study is to evaluate the safety and tolerability of VIT-45 in the treatment of Iron Deficiency Anemia
- Trial name
- NCT00740246
- Testing
- VIT-45
- Where
- United States
- Volunteers
- 594 people
- Sponsor
- American Regent, Inc.
Anemia
Study of the Efficacy of Two Doses of Ferrlecit in the Treatment of Iron Deficiency in Pediatric Hemodialysis Patients
This was a multi-center study in iron-deficient pediatric hemodialysis patients, whose legal guardian had provided signed informed consent and satisfied the inclusion and exclusion criteria.
- Trial name
- NCT00223964
- Testing
- Ferrlecit (sodium ferric gluconate complex in sucrose injection)
- Where
- 24 sites in United States, Mexico and 3 more
- Volunteers
- 59 people
- Sponsor
- Watson Pharmaceuticals